Last updated: February 13, 2026
What is the drug associated with NDC 63402-0308?
NDC 63402-0308 identifies Ruxolitinib (brand name Jakafi). It is a Janus kinase (JAK) inhibitor marketed primarily for myelofibrosis and polycythemia vera. Approved by the FDA in 2011, Jakafi generated approximately $2.4 billion in global sales in 2022.
Market Size and Growth
Current Market Landscape
- Prevalence of target conditions: Myelofibrosis affects roughly 3-6 per 1 million people annually in the U.S., with an estimated 14,000–17,000 patients. Polycythemia vera affects approximately 123 cases per 1 million universally.
- Patient pool estimates: U.S. market estimates range between 10,000–15,000 eligible patients for Ruxolitinib.
- Competitive landscape: Other JAK inhibitors include Fedratinib (Inrebic) and Baricitinib (Olumiant, off-label for hematologic conditions). There are no direct biosimilar approvals as of early 2023, sustaining high market exclusivity for Jakafi.
Growth Drivers
- Expanded indications: In 2022, the FDA approved Ruxolitinib for steroid-refractory acute graft-versus-host disease, broadening market scope.
- Orphan drug designation: Maintains exclusivity until at least 2031.
- Increasing diagnosis rates: Growing awareness and testing enhance patient identification.
Challenges
- High cost: The annual treatment cost exceeds $100,000, limiting access.
- Generic competition: No approved generics; biosimilars might disrupt the market post-patent expiry.
- Adverse effects: Cytopenias and infection risk may impact market penetration.
Price Projections
Current Pricing
- Average Wholesale Price (AWP): Estimated at approximately $6,000–$7,000 per month for a typical dose.
- Annual treatment cost: Around $72,000–$84,000, depending on dosing and payer agreements.
- Net price: Commercial payers achieve discounts ranging from 20% to 40%.
Future Pricing Trends
- Patent expiry: Patent protections extend until at least 2031; biosimilar entry anticipated post-2030.
- Price erosion: With biosimilar competition, initial reductions of 20%–30% are probable within 3–5 years post-generic entry.
- Market pressures: Payers' cost containment measures and potential biosimilars could reduce prices further, possibly reaching $50,000–$60,000 annually in 5–7 years.
Impact of Regulatory and Policy Dynamics
- Pricing regulations: Negotiations in Medicare and Medicaid could cap prices.
- Orphan drug policies: Continue to incentivize high prices due to small patient populations and exclusivity.
Future Market Trends and Projections (2023–2030)
| Year |
Projected Market Size |
Estimated Average Price |
Estimated Revenues |
| 2023 |
$2.4B |
$72,000/year |
$2.4B |
| 2025 |
$2.55B |
$68,000/year |
$2.5B |
| 2027 |
$2.7B |
$60,000/year |
$2.6B |
| 2030 |
$2.8B |
$50,000/year |
$2.4B |
Prices decline reflecting market entry of biosimilars, payer discounts, and expanded indications.
Key Takeaways
- Ruxolitinib commands high current prices driven by strong individual patient demand and patent protections.
- The market is expected to grow modestly, reaching approximately $2.8 billion by 2030.
- Price reductions of 20-30% are anticipated before or around clinical biosimilar approval, likely post-2030.
- Expansion into new indications and broader diagnosis awareness will sustain revenue levels despite price erosion.
- Payer negotiations and policy reforms will influence net pricing and overall market dynamics.
FAQs
1. When is biosimilar competition expected for Ruxolitinib?
Biosimilar approval in the U.S. could occur around 2030–2032, aligned with patent expiry and regulatory pathways for biosimilars.
2. How does pricing compare globally?
In markets like Europe and Canada, prices are generally lower due to cost containment policies, often 30-50% below U.S. levels.
3. What factors could influence future demand?
Market expansion depends on clinical advancements, broader indication approvals, and improved diagnosis of eligible patients.
4. Are there approved alternatives to Ruxolitinib?
Yes. Fedratinib (Inrebic) is approved for myelofibrosis and may serve as a secondary option but has a smaller market share.
5. What regulatory changes could impact prices?
Policies aimed at drug price transparency, patent reforms, and biosimilar promotion could lead to significant price adjustments.
Sources
- IQVIA, 2022. "Medicine Use and Spending in the U.S.: A Review of 2022 and Outlook for 2023."
- FDA, 2022. "Approval Package for Ruxolitinib (Jakafi)."
- EvaluatePharma, 2022. "Top 100 Drugs by Sales."
- American Society of Hematology, 2022. "Guidelines for Myelofibrosis Management."
- Medicaid and Medicare Policy Reports, 2022.
